cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off-the-shelf therapies for haematological cancers. The two companies will collaborate on the ...

Enzymes in the environment and in our bodies are quick to chop mRNA into pieces, making lab experiments difficult and the delivery of mRNA to our cells daunting. On top of that, mRNA strands are ...

With increasing interest in developing antifibrotic therapies, there is a need for cell lines that preserve the in vivo phenotype of human HSCs to elucidate pathways of human hepatic fibrosis. We ...